Woodline Partners’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$23.8M Buy
+715,500
New +$21.3M 0.09% 297
2025
Q3
Sell
-594,620
Closed -$21.4M 1046
2025
Q2
$21.4M Buy
594,620
+61,486
+12% +$2.29M 0.11% 272
2025
Q1
$21M Buy
+533,134
New +$17.9M 0.14% 221
2024
Q4
Sell
-2,565,322
Closed -$60M 997
2024
Q3
$60M Buy
2,565,322
+1,145,788
+81% +$25M 0.51% 46
2024
Q2
$25.3M Buy
1,419,534
+14,937
+1% +$238K 0.24% 135
2024
Q1
$21.4M Sell
1,404,597
-363,837
-21% -$5.8M 0.2% 162
2023
Q4
$30.2M Buy
1,768,434
+1,616,295
+1,062% +$18.8M 0.33% 91
2023
Q3
$1.27M Buy
152,139
+10,639
+8% +$148K 0.01% 430
2023
Q2
$3.51M Buy
+141,500
New +$3.65M 0.04% 346
2023
Q1
Sell
-2,562,100
Closed -$30.3M 773
2022
Q4
$30.3M Buy
2,562,100
+1,627,664
+174% +$11.8M 0.41% 57
2022
Q3
$5.53M Buy
+934,436
New +$6.13M 0.08% 274
2021
Q4
Sell
-106,932
Closed -$3.56M 787
2021
Q3
$3.56M Buy
106,932
+4,952
+5% +$153K 0.06% 307
2021
Q2
$3.96M Sell
101,980
-824,786
-89% -$32.4M 0.07% 248
2021
Q1
$44.7M Buy
926,766
+893,514
+2,687% +$42.9M 0.99% 22
2020
Q4
$1.73M Sell
33,252
-166,623
-83% -$5.63M 0.05% 199
2020
Q3
$5.35M Sell
199,875
-132,777
-40% -$3.06M 0.18% 125
2020
Q2
$6.48M Buy
+332,652
New +$5.36M 0.26% 94

Other funds holding TGTX

Woodline Partners's TGTX Position: Q1 2026 in Review

Woodline Partners opened a new position in TG Therapeutics (TGTX) in Q1 2026: 715,500 shares worth $23.8M. The stake represents 0.09% of the portfolio and ranks #297 among its holdings. This is a return to the name: Woodline Partners previously reported a position in TGTX as recently as Q2 2025.

Woodline Partners first reported a position in TGTX in Q2 2020 and has held it in 17 quarters since. The position peaked at $60M in Q3 2024. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Woodline Partners held 715,500 shares of TG Therapeutics worth $23.8M as of Q1 2026.
  • TG Therapeutics was a new Woodline Partners position in Q1 2026.
  • TG Therapeutics made up 0.09% of Woodline Partners's portfolio in Q1 2026, its #297 holding.
  • Woodline Partners first reported a position in TG Therapeutics in Q2 2020 and has held it in 17 quarters since.
  • Woodline Partners's TG Therapeutics position peaked at $60M in Q3 2024.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.